stockportfolio.pro
InMode Ltd. (INMD)
Healthcare · Medical Devices · NasdaqGS
InMode Ltd. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $454.27M | $492.05M | $394.82M | $370.50M |
| Gross profit | $380.79M | $411.34M | $317.07M | $290.97M |
| Net income | $161.52M | $197.92M | $181.28M | $93.83M |
| Net margin | 35.6% | 40.2% | 45.9% | 25.3% |
Source: InMode Ltd. SEC filings (10-K).
What growth is priced into INMD stock?
At today's market cap of $817.88M, InMode Ltd. is priced for free-cash-flow growth of about -2.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $84.28M from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 4 years of InMode Ltd. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track INMD in your portfolio →
InMode Ltd. financial history by metric
About InMode Ltd.
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.
InMode Ltd. — frequently asked questions
What is InMode Ltd.'s revenue?
InMode Ltd. (INMD) reported revenue of $370.50M for fiscal year 2025, down 6.2% from the prior year, according to its SEC filings.
Is InMode Ltd. profitable?
Yes. INMD earned net income of $93.83M in fiscal 2025, a net margin of 25.3%.
What is INMD's P/E ratio?
InMode Ltd. trades at a price-to-earnings ratio of about 10.0 based on the latest data in our nightly-refreshed cache.
How fast is InMode Ltd. growing?
INMD's revenue grew at roughly -6.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does InMode Ltd. have?
As of fiscal year 2025, INMD carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is InMode Ltd.'s gross margin?
INMD's gross margin was 78.5% in fiscal 2025 — gross profit of $290.97M on revenue of $370.50M.
What is InMode Ltd.'s market cap?
InMode Ltd. (INMD) has a market capitalization of about $817.88M, based on the latest data in our nightly-refreshed cache.
When does InMode Ltd.'s fiscal year end?
INMD's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into INMD stock?
At today's market cap of $817.88M, InMode Ltd. is priced for free-cash-flow growth of about -2.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $84.28M from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from InMode Ltd.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.